Lonza Expands Bioconjugation Facility and Announces Approval of Third Commercial ADC

24-Jul-2019 - Lonza announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third antibody-drug-conjugate (ADC) produced at the site. Building on 12 years of experience in the exacting bioconjugation space, Lonza’s expansion ...

Sanofi and Lonza Enter into a Strategic Partnership to Establish a Large-Scale Biologics Production Facility

28-Feb-2017 - Sanofi and Lonza announced that they have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland. The strategic partnership in the form of a joint venture combines the strong biologics ...

Lonza and BioWa sign license agreements with Pfizer

31-Jul-2013 - BioWa, Inc. and Lonza announced that they have entered into research agreements with Pfizer Inc. allowing the use of the POTELLIGENT® CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer’s pipeline. POTELLIGENT® CHOK1SV is a host cell line for ...

Lonza and LFB Enter Manufacturing Agreement

15-Jul-2009 - Lonza and LFB announced the signing of an agreement to manufacture a monoclonal anti-RhD antibody developed by LFB. Under this agreement, the process developed by LFB will be transferred to Lonza which will provide GMP manufacturing services for supporting the phase III clinical program. Lonza, ...

Medarex and Lonza Sign Collaboration Agreement for the Supply of Antibody-Based Products

Agreement Includes Manufacture of Antibodies and Antibody Drug Conjugates

10-Jul-2009 - Lonza and Medarex, Inc. announced that they have signed an agreement giving Medarex the option to work with Lonza as a collaboration partner to provide manufacturing services in support of the development and commercialization of Medarex’s pipeline of therapeutic proteins and antibody drug ...

Lonza enters a commercial license agreement with Cytos

Gene Expression System with a new Expression Technology

02-Feb-2004 - Lonza Group Ltd and Cytos Biotechnology AG announce that they have entered into a collaboration in which Cytos gives Lonza access to its novel transient expression system for therapeutic proteins. Lonza has been granted a sole license to manufacture therapeutic proteins for preclinical studies, ...

Lonza Biologics and Alexion Pharmaceuticals sign agreement for commercial manufacturing

07-Jan-2003 - Alexion Pharmaceuticals, Inc. announced the execution of a large scale product supply agreement with Lonza Biologics for the long term commercial manufacture of its C5 complement inhibitor antibody, eculizumab. Alexion recently announced promising clinical results from clinical studies evaluating ...